Privacy Statement   Terms & Conditions   Sitemap  
  Diseases   Research   About us  
Facts & Figures News Career Baxter Worldwide
 
Press Releases

  Baxter Receives EMEA Positive Opinion for CELVAPAN, the First Cell Culture-based Pandemic Flu Vaccine

Clinical data from a Phase III and subsequent booster study demonstrate safety, immune response and cross-protective memory DEERFIELD ...

Date: 2008/12/18 » read more

  The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine

Click here to view The New England Journal of Medicine manuscript. ...

Date: 2008/06/11 » read more

  U.S. Department of Health and Human Services Completes Funding of 2006 Contract Award to CSCīs DVC and Baxter

EL SEGUNDO, Calif. and DEERFIELD, Ill., Nov. 27 – Computer Sciences Corporation (NYSE: CSC) today announced that DynPort Vaccine Company LLC (DV ...

Date: 2007/11/27 » read more

  Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health

DEERFIELD, Ill., USA, and LONDON, UK, August 16, 2007 – Baxter International Inc. (NYSE:BAX) announced today that Baxter’s European subsid ...

Date: 2007/08/16 » read more

  Baxter Announces Preliminary Phase I/II Data for Seasonal Influenza Vaccine Candidate

Key safety, immunogenicity data presented at Options for the Control of Influenza VI Conference in Toronto DEERFIELD, Ill., July 23, 2007 & ...

Date: 2007/07/23 » read more

  Baxter Supports Improved Access to Pandemic Influenza Treatment in the Developing World

Company pledges to support World Health Organization program DEERFIELD, Ill., (June 13, 2007) — Baxter International Inc. (NYSE: BAX) ...

Date: 2007/06/13 » read more

  Baxter Announces Final Phase I/II Data and Initiation of Phase III Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine

DEERFIELD, Ill., March 29, 2007 – Baxter International Inc. (NYSE: BAX) today announced final Phase I/II data for its adjuvant-free investig ...

Date: 2007/04/01 » read more

  Baxter receives preparedness contract from Austrian Ministry of Health for Pandemic Influenza Vaccine

VIENNA and DEERFIELD, Ill., November 22, 2006 -- Baxter Healthcare SA today announced that the Austrian Ministry of Health has entered int ...

Date: 2006/11/23 » read more

  Baxter Announces Safety and Immunogenicity Results from Phase I/II Clinical Trial of Cell-Based Candidate H5N1 Pandemic Vaccine

Deerfield, Ill., October 4, 2006 Baxter International Inc. (NYSE: BAX) today announced results from a preliminary evaluation of its Phase I ...

Date: 2006/10/26 » read more

  Baxter initiates clinical study with cell-based candidate H5N1 Pandemic Vaccine

Deerfield, Ill., July 5, 2006 Baxter International Inc. (NYSE: BAX) today announced that it has initiated a Phase I/II clinical trial to tes ...

Date: 2006/07/11 » read more

 
« previous   1 | 2 | 3 | 4   next »
 
 
  » find


 

Baxter Receives EMEA Positive Opinion for CELVAPAN, the First Cell Culture-based Pandemic Flu Vaccine
» read more

The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine
» read more

U.S. Department of Health and Human Services Completes Funding of 2006 Contract Award to CSCīs DVC and Baxter
» read more

 
Baxter Vaccines Industriestrasse 67, A-1221 Wien, Tel: +43-1-20100,